Nasze produkty charakteryzuje solidno oraz zgodno z zasadami ergonomii
The glucose-dependent nature of insulin secretion with GLP-1 therapy represents a significant safety advantage
Patients are empowered to embrace what they have accomplished, a healthier, stronger, more confident self, irrespective of how their skin appears
(2023) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Obesity, insulin resistance, diabetes and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity and Metabolism)
Retatrutide is currently an Investigational New Drug (IND) under Phase 3 clinical investigation and has not received FDA approval for any therapeutic indication